Paul S Bourdon

Dr. Paul S Bourdon

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Linear Algebra and its Applications
Verified
Journal Article
Closed access
PBPaul S Bourdon
Paul S Bourdon
CKCarlos Kubrusly
Carlos Kubrusly
TLTrieu Le
Trieu Le
DTDerek Thompson
Derek Thompson

1 January 2016 in Journal of Operator Theory
Verified
Journal Article
Closed access
PBPaul S Bourdon
Paul S Bourdon

23 March 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
PBPaul S Bourdon
Paul S Bourdon
SPSpiro P. Pantazatos
Spiro P. Pantazatos
Why a major study on myocarditis risk following COVID vaccination should not influence public-health policy

28 May 2023 in arXiv
Verified
Preprint
Open access
PDF file
PBPaul S Bourdon
Paul S Bourdon
CKCarlos Kubrusly
Carlos Kubrusly
TLTrieu Le
Trieu Le
DTDerek Thompson
Derek Thompson
We focus on two problems relating to the question of when the product of two posinormal operators is posinormal, giving (1) necessary conditions and sufficient conditions for posinormal operators to have closed range, and (2) sufficient conditions for the product of commuting closed-range posinormal operators to be posinormal with closed range. We also discuss the relationship between posinormal operators and EP operators (as well as hypo-EP operators), concluding with a new proof of the Hartwig-Katz Theorem, which characterizes when the product of posinormal operators on $\CC^n$ is posinormal.

11 October 2022 in arXiv
Verified
Preprint
Open access
PDF file
PBPaul S Bourdon
Paul S Bourdon
CKC. S. Kubrusly
C. S. Kubrusly
DTDerek Thompson
Derek Thompson
A bounded linear operator $A$ on a Hilbert space $\mathcal{H}$ is posinormal if there exists a positive operator $P$ such that $AA^{*} = A^{*}PA$. We show that if $A$ is posinormal with closed range, then $A^n$ is posinormal and has closed range for all integers $n\ge 1$. Because the collection of posinormal operators includes all hyponormal operators, we obtain as a corollary that powers of closed-range hyponormal operators continue to have closed range. We also present a simple example of a closed-range operator $T: \mathcal{H}\to \mathcal{H}$ such that $T^2$ does not have closed range.

10 February 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
PBPaul S Bourdon
Paul S Bourdon
RDRam Duriseti
Ram Duriseti
HGH. Christian Gromoll
H. Christian Gromoll
DDDyana K Dalton
Dyana K Dalton
KBKevin Bardosh
Kevin Bardosh
AKAllison E. Krug
Allison E. Krug
Background: The U.S. Food and Drug Administration (FDA) conducted a benefit–risk assessment for Moderna’s COVID vaccine mRNA-1273 prior to its full approval, announced 31 January 2022. The FDA’s assessment focused on males 18–64 years old because its risk analysis was limited to vaccine-attributable myocarditis/pericarditis (VAM/P), given the excess risk among males. The FDA’s analysis concluded that vaccine benefits outweighed risks, even for 18–25-year-old males (those at highest VAM/P risk). We reanalyze the FDA’s benefit–risk assessment using information available through the third week of January 2022 and focusing on 18–25-year-old males. Methods: We develop a benefit–risk model, extending the FDA’s, that can stratify benefits and risks of vaccination by prior-infection and comorbidity status. We use the FDA’s framework but apply our model to account for benefits derived from prior COVID infection, while also accounting for finer age stratification in COVID-hospitalization rates, incidental hospitalizations (those of patients who test positive for COVID but receive treatment for something else), more realistic projections of Omicron-infection rates, and more accurate VAM/P rates. Results: With hospitalizations as the principal endpoint of the analysis (those prevented by vaccination vs. those caused by VAM/P), our model finds vaccine risks outweighed benefits for 18–25-year-old males, except in scenarios projecting implausibly high Omicron-infection prevalence. Our assessment suggests that mRNA-1273 vaccination of 18–25-year-old males generated between 8% and 52% more hospitalizations for VAM/P compared to COVID hospitalizations prevented (over a five-month period of vaccine protection assumed by the FDA). The preceding assessment uses model inputs based on data available at the time of the FDA’s mRNA-1273 assessment. Moreover, these inputs as well as model outputs are validated by subsequently available data. Conclusions: The outcome of a vaccine benefit–risk assessment may be dramatically impacted by accounting for the benefits derived from prior infection by the vaccine-targeted disease. To increase public confidence in vaccines and thereby reduce vaccine hesitancy, public-health agencies should employ benefit–risk models capable of supporting stratification of vaccination recommendations not only based on age and sex but also on prior-infection and comorbidity status.